| | |
Good morning, 360! | What does the Market have in store for us this week?!?Join us today for LIVE trading in the Market Master's Room. Friends don't let friends trade alone, that's for sure! | | | FOCUS LIST🔎 | NLSP - Up over 70% in the pre-market after announcing binding term sheet to merge with Kadimastem | LGVN - Up over 25% in pre after presenting Phase 2a Alzheimer's treatment results | LIPO - Up over 70% in pre after initiating Phase 2a trial for LP-310 in Oral Lichen Planus, enrolls first patients | | *sponsored by Sica Media | Go to your favorite platform and pull up Actinium Pharmaceuticals, Inc. (ATNM) right now, and I'll show you what I see. | On the chart below, you'll see the 5-minute price action over the last week, including the big day we had on Tuesday last week… | | That big day established a new range for ATNM, from around $7.50 up to over $8.50. | The stock has been building what looks like a "bull flag" to me over the last few days. I added the lines to this range so you can see it. | When a flag pattern gets very tight like this, it usually resolves with a strong breakout (hopefully to the upside!) | While I am cautious the break could be lower, I will keep a close eye on a closing price under $7.70, which would tell me this just isn't ready for the next move up yet. | However, a break over $8 again could be just the spark ATNM needs to re-test the upper range from last week, and possibly even $9 again. | After that, I don't see why ATNM couldn't make a run for its all-time high again just over $10? | Make sure you do your due diligence if you decide to trade anything, as nothing is every guaranteed when it comes to trading. For my full thoughts on ATNM, see this page! | *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. |
|
| | HOTLIST🔥 | NLSP - Up over 70% in the pre-market after announcing binding term sheet to merge with Kadimastem | NLS Pharmaceutics AG (NLSP) is a clinical-stage biopharmaceutical company that engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. | In the pre-market this morning the company announced a binding term sheet to merge with Kadimastem. | The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy platform. | The combined company is expected to operate under the name Kadimastem and be traded on the Nasdaq Capital Market. | Under the proposed terms, existing Kadimastem shareholders will hold 85% of the issued and outstanding shares of the merged company and the existing shareholders of NLS will hold the remaining 15% of the issued and outstanding shares of NLS. | Kadimastem is a clinical stage cell therapy company whose shares are listed on the Tel Aviv Stock Exchange "KDST.TA". Kadimastem is developing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, Kadimastem's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. | Shares of NLSP traded up over 70% in the pre-market after the announcement. | | The first target for bulls is the pre-market high at $0.3750. | Beyond that, $0.40, $0.4597, $0.50, $0.55, $0.60, $0.70 and $0.75 come into play. | Below $0.3750, targets to the downside are $0.34, $0.30, $0.28, $0.24 and then a gap fill at $0.19. | | LGVN - Up over 25% in pre after presenting Phase 2a Alzheimer's treatment results | Longeveron Inc. (LGVN) is a clinical stage biotechnology company that develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. | Over the weekend the company presented study results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in mild Alzheimer's disease at the Alzheimer's Association International Conference® (AAIC). | – Featured Research Session oral presentation highlights findings that show Lomecel-B™ improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's Disease – | – Study meets its key objectives to advance data supporting favorable benefit/risk profile, support target engagement, and provide additional support for the efficacy profile of Lomecel-B™ – | The stock traded up over 25% in the pre-market in reaction to the findings presented the conference. | | The $4.08 area acted as support in the pre-market and now becomes a potential level of resistance. | Above it, targets to the upside are $4.40, $4.60, $4.80, $5, and then the pre-market high at $5.10. Beyond that, $6 and $8 come into play. | Below $4.08, there is a gap fill at $3.44 with $3 below that. | | Options Trading for Small Accounts | Jason Bond's $2,000 Small Account Journey |  | Results not typical. Trading is hard. Nothing is guaranteed. |
|  | Results not typical. Trading is hard. Nothing is guaranteed. |
| Start YOUR Journey Today! | NEW 5-year Plan for as Little as … CLICK HERE |
|
| | LIPO - Up over 70% in pre after initiating Phase 2a trial for LP-310 in Oral Lichen Planus, enrolls first patients | Lipella Pharmaceuticals Inc. (LIPO) is a biotechnology company that focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. | Over the weekend, the company announced the enrollment of the first patients in its multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). | This chronic inflammatory condition, which affects over 6 million Americans, is characterized by mouth mucous membrane inflammation, pain, and ulceration, and lacks FDA-approved treatments. | LP-310 is designed to address the underlying causes of OLP, offering a promising alternative to current palliative treatments and delivering local concentration in the oral cavity, aiming to minimize systemic toxicity. | The trial is anticipated to conclude by mid-2025, with top-line data expected year-end 2024. | | The first target for bulls is the pre-market high at $0.9135. | Beyond that, $0.95, $1, $1.05, $1.10, $1.20, $1.30 and $1.60 come into play. | Below $0.9135, targets to the downside are $0.80, $0.75, $0.70, $0.65, $0.60, $0.50 and a gap to fill at $0.4041. | | MARKET NEWS 📰 | | | 👊 Make sure you are getting my mobile text alerts – text "RAGE" to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the "1" at the front!). Don't miss out! | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | *Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call "typical." | Just a quick heads up about this ad you're reading—as we've said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Sica Media for advertising Actinium Pharmaceuticals, Inc for a one day marketing program on July 29, 2024. We previously received thirty thousand dollars (cash) for advertising Actinium Pharmaceuticals, Inc for a one day marketing program on July 23, 2024, and seventeen thousand five hundred dollars for a one day marketing program on March 18, 2024. Both of these were from Sica Media who was compensated by a third party not affiliated with the Company. These amounts were paid by someone else not connected to Actinium Pharmaceuticals, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case. | Now, diving right into Actinium Pharmaceuticals, Inc might sound exciting. But remember, it's like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you're doing. That's why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r. | Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We're simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We're obviously biased in our writing. We're not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as "forward-L00king statements" under the securities acts, so take those with a grain of salt. As with all forecasts, they're not set in stone, often wrong, and we certainly can't know where the Company's earnings, business, or share price will be tomorrow or a year from now. | Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, | Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep's with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization. | So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture. |
|
Tidak ada komentar:
Posting Komentar